MEK162 for Patients With RAS/RAF/MEK Activated Tumors



Status:Active, not recruiting
Healthy:No
Age Range:18 - 100
Updated:4/23/2016
Start Date:October 2013

Use our guide to learn which trials are right for you!

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors

The purpose of this signal seeking study is to determine whether treatment with MEK162
demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic
malignancies to warrant further study

This is a phase II, open label study to determine the efficacy and safety of treatment with
MEK162 in patients with a diagnosis of select solid tumors or hematological malignancies
that have been pre-identified (prior to study consent) to have activations of the
RAS/RAF/MEK pathway and whose disease has progressed on or after standard treatment.

Genomic profiling is becoming more accessible to patients and their physicians. This is a
signal-seeking study to match patients with mutations in RAF, RAS, NF1 or MEK to the
ATP-noncompetitive MEK 1/2 inhibitor, MEK162. Pre-identification of these mutations or
activations in the pathway will be performed locally at a CLIA certified laboratory prior to
screening for participation on the trial.

Once the patient has been identified, treating physicians who are qualified investigators
may contact Novartis to consider enrollment in this study. For the purpose of this study,
genomic profiling is not considered part of screening. Informed consent must be signed
before any screening activities take place. Once eligibility (screening criteria met) has
been confirmed by Novartis, the patient will initiate therapy with single agent MEK162. The
patient may not receive any additional anti-cancer therapy during treatment with MEK162.

Patients will continue to receive study treatment until disease progression (assessed by
RECIST 1.1 or appropriate hematologic response criteria), unacceptable toxicity, death or
discontinuation from study treatment for any other reason (e.g., withdrawal of consent,
start of a new anti-neoplastic therapy or at the discretion of the investigator), otherwise
known as End of Treatment. All patients who discontinue from study treatment due to disease
progression must have their progression clearly documented.

Disease assessment (per RECIST 1.1 or appropriate hematological response criteria) will be
performed every 8 weeks (±4 days) after first dose of study drug (Day 1 of every odd cycle),
until disease progression or end of treatment, whichever occurs first. The frequency of
disease assessment may be reduced to every 12 weeks for patients who have at least 4
post-baseline disease assessments and are clinically stable (except AML and MM patients).
Scans will be assessed locally by the investigator. After discontinuation of treatment,
patients, regardless of reason for treatment discontinuation, will be followed for safety
for 30 days after the last dose.

All patients will be followed for survival status every 3 months for 2 years after the last
patient has enrolled in the study regardless of treatment discontinuation reason (except if
consent is withdrawn or patient is lost to follow-up.)

Inclusion Criteria:

- Patient has a confirmed diagnosis of a select solid tumor (except for primary
diagnosis of pancreatic cancer, biliary cancer, colorectal cancer, low grade serous
ovarian cancer, melanoma) or hematologic malignancy (except for primary diagnosis of
chronic myelomonocytic leukemia).

- Patients must be pre-identified as having a tumor with a mutation in RAF, RAS, NF1 or
MEK at a CLIA certified laboratory

- Patient must have received at least one prior treatment for recurrent, metastatic and
/or locally advanced disease and for whom no standard therapy options are anticipated
to result in a durable remission.

- Patient must have progressive and measurable disease as per RECIST 1.1. or other
appropriate hematological guidelines.

- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

Exclusion Criteria:

- Patient has received prior treatment with MEK162.

- Patients with primary CNS tumor or CNS tumor involvement

- History of retinal degenerative disease

- History or current evidence of central serous retinopathy (CSR) or retinal vein
occlusion (RVO)

- Any ophthalmopathy visible at screening that would be considered a risk factor for
CSR or RVO by the ophthalmologist

- Patients who have neuromuscular disorders that are associated with elevated CK
We found this trial at
68
sites
Jacksonville, Florida 32256
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Albuquerque, New Mexico 87106
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
?
mi
from
Athens, GA
Click here to add this to my saved trials
Bend, Oregon 97701
?
mi
from
Bend, OR
Click here to add this to my saved trials
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Boulder, Colorado 80304
?
mi
from
Boulder, CO
Click here to add this to my saved trials
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Coon Rapids, Minnesota 55433
?
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Dallas, Texas 75251
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
103 Seeley Mudd Building
Durham, North Carolina 27710
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Eugene, OR
Click here to add this to my saved trials
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
?
mi
from
Fargo, ND
Click here to add this to my saved trials
?
mi
from
Fayetteville, AR
Click here to add this to my saved trials
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
?
mi
from
Hollywod, FL
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
?
mi
from
Kalispell, MT
Click here to add this to my saved trials
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
?
mi
from
Kennewick, WA
Click here to add this to my saved trials
Lacey, Washington 98503
?
mi
from
Lacey, WA
Click here to add this to my saved trials
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Memphis, Tennessee 38120
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Miami Beach, Florida 33140
?
mi
from
Miami Beach, FL
Click here to add this to my saved trials
8800 W. Doyne Avenue
Milwaukee, Wisconsin 53226
(414) 805-6840
Medical College of Wisconsin Cancer Center Cancer touches everyone in our community, and for many,...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
?
mi
from
Mobile, AL
Click here to add this to my saved trials
?
mi
from
Murray, UT
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Natrona Heights, Pennsylvania 15065
?
mi
from
Natrona Heights, PA
Click here to add this to my saved trials
New Brunswick, New Jersey 08902
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
?
mi
from
New Haven, CT
Click here to add this to my saved trials
?
mi
from
Norwalk, CT
Click here to add this to my saved trials
?
mi
from
Norwich, CT
Click here to add this to my saved trials
?
mi
from
Ocala, FL
Click here to add this to my saved trials
?
mi
from
Ocoee, FL
Click here to add this to my saved trials
Park Ridge, Illinois 60068
?
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Peoria, Illinois 61615
?
mi
from
Peoria, IL
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pismo Beach, California 93449
?
mi
from
Pismo Beach, CA
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Reston, VA
Click here to add this to my saved trials
?
mi
from
Rockville, MD
Click here to add this to my saved trials
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
Sedona, AZ
Click here to add this to my saved trials
?
mi
from
St. Louis, MO
Click here to add this to my saved trials
Stamford, Connecticut 06902
?
mi
from
Stamford, CT
Click here to add this to my saved trials
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
?
mi
from
Troy, NY
Click here to add this to my saved trials
?
mi
from
Tyler, TX
Click here to add this to my saved trials
?
mi
from
Webster, TX
Click here to add this to my saved trials
?
mi
from
Willow Grove, PA
Click here to add this to my saved trials